Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00496548 · ClinicalTrials.gov registry record · NA
Urinary Prostaglandin E Metabolite (PGE-M), A Metabolite of Prostaglandin E2 (PGE2): A Novel Biomarker of Crohn's Disease Activity
A NA study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 159
- Enrollment target
NCT00496548 is a NA study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 159 participants.
The verdict
NCT00496548, a NA study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 159 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether urinary PGE-M levels correlate with Crohn's disease activity and to compare how well urinary PGE-M correlates with other non-invasive biomarkers of disease activity such as C-reactive protein (CRP) and fecal calprotectin.
Interventions
- PROCEDURE Fecal calprotectin
- PROCEDURE Urinary PGE-M Level
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2007-08 |
| Est. Completion | 2015-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00496548
The ClinicalTrials.gov registry entry for NCT00496548 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fecal calprotectin is the first listed.
NCT00496548 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00496548 about?
NCT00496548 is a clinical study titled "Urinary Prostaglandin E Metabolite (PGE-M), A Metabolite of Prostaglandin E2 (PGE2): A Novel Biomarker of Crohn's Disease Activity". The purpose of this study is to determine whether urinary PGE-M levels correlate with Crohn's disease activity and to compare how well urinary PGE-M correlates with other non-invasive biomarkers of disease activity such as C-reactive protein (CRP) and fecal calprotectin.
What is the current status of trial NCT00496548?
This trial is currently completed. It is a NA study. The enrollment target is 159 participants. The study started on 2007-08. Estimated completion is 2015-12.
What interventions are being tested in trial NCT00496548?
The interventions under investigation include: Fecal calprotectin (PROCEDURE), Urinary PGE-M Level (PROCEDURE).
Who is sponsoring clinical trial NCT00496548?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.